Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1505-1513

  Vrouenraets, Maarten B ^a   Visser, Gerard W M ^b   Stewart, Fiona A ^c   Stigter, Marijke ^a   Oppelaar, Hugo ^c   Postmus, Pieter E ^a   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

META TETRAHYDROXYPHENYLCHLORIN; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CELL KILLING; CONJUGATE; CYTOTOXICITY; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SOLUBILITY; TISSUE INJURY;

EID: 0033119888     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Weishaupt, K. R., Gomer, C. J., and Dougherty, T. J. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res., 36: 2326-2329, 1976.
2. Penning, L. C., Tijssen, K., Boegheim, J. P. J., van Steveninck, J., and Dubbelman, T. M. A. R. Relationship between-photodynamically induced damage to various cellular parameters and loss of clonogenicity in different cell types with hematoporphyrin derivative as sensitizer. Biochim. Biophys. Acta, 1221: 250-258, 1994.
3. Henderson, B. W., Waldow, S. M., Mang, T. S., Potter, W. R., Malone, P. B., and Dougherty, T. J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res., 45: 572-576, 1985.
4. Krosl, G., Korbelik, M., and Dougherty, G. J. Induction of immune cell infiltration into murine SCCVII tumour by Photofrin-based pholodynamic therapy. Br. J. Cancer, 71: 549-555, 1995.
5. Fromm, D., Kessel, D., and Webber, J. Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Arch. Surg., 131: 667-669, 1996.
6. Nseyo, U. O., and Lamm, D. L. Therapy of superficial bladder cancer. Semin. Oncol., 23: 598-604, 1996.
7. Furuse, K., Fukuoka, M, Kato, H., Horai, T., Kubota, K., Kodama, N., Kusunoki, Y., Takifuji, N., Okunaka, T., Konaka, C., Wada, H., and Hayata, Y. A prospective phase II study on photodynamic therapy with Photofrin II for centrally located early-stage lung cancer. J. Clin. Oncol., 11: 1852-1857, 1993.
8. Lofgren, L. A., Hallgren, S., Nilsson, E., Westerborn, A., Nilsson, C., and Reizenstein, J. Photodynamic therapy for recurrent nasopharyngeal cancer. Arch. Otolaryngol. Head Neck Surg., 121: 997-1002, 1995.
9. Bonnett, R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem. Soc. Rev., 24: 19-33, 1995.
10. Dilkes, M. G., DeJode, M. L., Rowntree-Taylor, A., McGilligan, J. A., Kenyon, G. S., and McKelvie, P. mTHPC photodynamic therapy for head and neck cancer. Lasers Med. Sci., 11: 23-29, 1996.
11. Savary, J-F., Monnier, P., Fontolliet, C., Wagnières, G., Braichotte, D., and Van den Bergh, H. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with meta-tetrahydroxyphenylchlorin. Arch. Otolaryngol. Head Neck Surg., 123: 162-168, 1997.
12. Pèlegrin, A., Folli, S., Buchegger, F., Mach, J-P., Wagnières, G., and Van den Bergh, H. Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer (Phila.), 67: 2529-2537, 1991.
13. Folli, S., Wagnières, G., Pèlegrin, A., Calmes J-M., Braichotte, D., Buchegger, F., Chalandon, Y., Hardman, N., Heusser, N., Givel, J. C., Chapuis, G., Châtelain, A., Van den Bergh, H., and Mach, J-P. Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric monoclonal antibodies against carcinoembryonic antigen. Proc. Natl. Acad. Sci. USA, 89: 7973-7977, 1992.
14. Folli, S., Westermann, P., Braichotte, D., Pèlegrin, A., Wagnières, G., Van den Bergh, H., and Mach, J-P. Antibody-indocyanin conjugates for immunodetection of human squamous cell carcinoma in nude mice. Cancer Res., 54: 2643-2649, 1994.
15. Quak, J. J., Van Dongen, G. A. M. S., Balm, A. J. M., Brakkee, J. P. G., Scheper, R. J., Snow, G. B., and Meijer, C. J. L. M. A 22-kDa surface antigen detected by monoclonal antibody E48 is exclusively expressed in stratified squamous and transitional epithelia. Am. J. Pathol., 136: 191-197, 1990.
16. Schrijvers, A. H. G. J., Quak, J. J., Uyterlinde, A. M., Van Walsum, M., Meijer, C. J. L. M., Snow, G. B., and Van Dongen, G. A. M. S. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res., 53: 4383-4390, 1993.
17. 2. J. Nucl. Med., 35: 775-783, 1994.
18. 2 in patients with head and neck cancer. Clin. Cancer Res., 1: 277-286, 1995.
19. 99mTc-labeled monoclonal antibody U36, and its biodistribution in patients with head and neck cancer. Clin. Cancer Res., 1: 591-598, 1995.
20. Brakenhoff, R. H., Van Gog, F. B., Looney, J. E., Van Walsum, M., Snow, G. B., and Van Dongen, G. A. M. S. Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol. Immunother., 40: 191-200, 1995.
21. Van Hal, N. L. W., Van Dongen, G. A. M. S., Rood-Knippels, E. M. C., Van der Valk, P., Snow, G. B., and Brakenhoff, R. H. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer, 68: 520-527, 1996.
22. Murthy, U., Basu, A., Rodeck, U., Herlyn, M., Ross, A. H., and Das, M. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGR-receptor polypeptide. Arch. Biochem. Biophys., 252: 549-560, 1987.
23. Stanton, P., Richards, S., Reeves, J., Nikolic, M., Edington, K., Clark, L., Robertson, G., Souter, D., Mitchell, R., Hendler, F. J., Cooke, T., Parkinson, E. K., and Ozanne, B. W. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br. J. Cancer, 70: 427-433, 1994.
24. Atlas, I., Mendelsohn, J., Baselga, J., Masui, H., Fair, W. R., and Kumar, R. Growth regulation of human renal carcinoma cells: role of transforming growth factor-α. Cancer Res., 52: 3335-3339, 1992.
25. Liberman, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., and Soreq, H. Expression of EGF receptors in human brain tumors. Cancer Res., 44: 753-760, 1984.
26. Yoshida, K., Kyo, E., Tsuda, T., Tsujino, T., Ito, M., and Tahara, E. EGF and TGF-α, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. Int. J. Cancer, 45: 131-135, 1990.
27. Neal, D. E., Bennet, M. K., Hall, R. R., Marsh, C., Abel, P. D., Sainsbury, J. R. C., and Harris, A. L. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet, 1: 366-368, 1985.
28. Gullick, W. J., Marsden, J. J., Whittle, N., Ward, B., Bobrow, L., and Waterfield, M. D. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res., 46: 285-292, 1986.
29. Hendler, F. J., and Ozanne, B. W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest., 74: 647-651, 1984.
30. Fitzpatrick, S. L., Brightwell, J., Wiltliff, J. L., Barrows, G. H., and Schultz, G. S. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen and progestin receptor levels. Cancer Res., 44: 3448-3453, 1984.
31. Sunada, H., Magun, B. E., Mendelsohn, J., and MacLeod, C. L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA, 83: 3825-3829, 1986.
32. Modjtahedi, H., Hickish, T., Nicolson, M., Moore, J., Styles, J., Eccles, S., Jackson, E., Salter, J., Sloane, J., Spencer, L., Priest, K., Smith, I., Dean, C., and Gore, M. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer, 73: 228-235, 1996.
33. Bier, H., Reiffen, K. A., Haas, I., and Stasiecki, P. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur. Arch. Oto-Rhino-Laryngol., 252: 433-439, 1995.
34. Brakenhoff, R. H., Gerretsen, M., Knippels, E. M. C., Van Dijk, M., Van Essen, H., Olde Weghuis, D., Sinke, R. J., Snow, G. B., and Van Dongen, G. A. M. S. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J. Cell Biol., 129: 1677-1689, 1995.
35. Haisma, H. J., Hilgers, J., and Zurawski, V. R. Iodination of monoclonal antibodies for diagnosis and therapy using a convenient one-vial method. J. Nucl. Med., 27: 1890-1895, 1986.
36. Lindmo, T., Boven, E., Luttita, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
37. Whelpton, R., Michael-Titus, A. T., Jamdar, R. P., Abdillahl, K., and Grahn, M. F. Distribution and excretion of radiolabeled Temoporfin in a murine tumor model. Photochem. Photobiol., 63: 885-891, 1996.
38. Veenhuizen, R., Oppelaar, H., Ruevekamp, M., Schellens, J., Dalesio, O., and Stewart, F. Does tumour uptake of Foscan determine PDT efficacy? Int. J. Cancer, 73: 236-239, 1997.
39. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
40. Reist, C. J., Garg, P. K., Alston, K. L., Bigner, D. D., and Zalutsky, M. R. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res., 56: 4970-4977, 1996.
41. Wargalla, U. C., and Reisfeld, R. A. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc. Natl. Acad. Sci. USA, 86: 5146-5150, 1989.
42. Mew, D., Wat, C-K., Towers, G. H. N., and Levy, I. G. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol., 130: 1473-1477, 1983.
43. Davis, N., Liu, D., Jain, A. K., Jiang, S-Y., Jiang, F., Richter, A., and Levy, J. G. Modified polyvinyl alcohol-benzoporphyrin derivative conjugates as phototoxic agents. Photochem. Photobiol., 57: 641-647, 1993.
44. Goff, B. A., Blake, J., Bamberg, M. P., and Hasan, T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br. J. Cancer, 74: 1194-1198, 1996.
45. 6 conjugates. Proc. Natl. Acad. Sci. USA, 83: 8744-8748, 1986.
46. Boniface, G. R., Izard, M. E., Walker, K. Z., McKay, D. R., Soby, P. J., Turner, J. H., and Morris, J. G. Labeling of monoclonal antibodies with Samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy. J. Nucl. Med., 30: 683-691, 1989.
47. 131I-labeled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer. Int. J. Cancer, 8: 43-48, 1994.
48. Van Gog, F. B., Visser, G. W. M., Klok, R., van der Schors, R., Snow, G. B., and van Dongen, G. A. M. S. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chclated groups and biodistribution characteristics. J. Nucl. Med., 37: 352-362, 1996.
49. Westermann, P., Glanzmann, T., Andrejevic, S., Braichotte, D. R., Forrer, M., Wagnières, G. A., Monnier, P., Van den Bergh, H., Mach, J-P., and Folli, S. Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int. J. Cancer, 76: 842-850, 1998.
50. 6 alone. Biochem. Int., 26: 445-450, 1992.
51. Jiang, F. N., Allison, B., Liu, D., and Levy, J. G. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems. J. Controlled Release, 19: 41-58, 1992.